Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Lands Exclusive License for Aarhus U Hospital Prostate Cancer Biomarkers

NEW YORK (GenomeWeb) – Exiqon today announced that it has entered into an exclusive agreement with Aarhus University Hospital to license prostate cancer biomarkers discovered and validated by the hospital.

The biomarkers include gene-specific methylation patterns that are associated with the aggressiveness of prostate cancer. The epigenetic biomarkers have been validated in two independent cohorts, consisting of over 400 patients with a follow-up period of 10 years.

"We rarely come across biomarkers with such a promising potential as we have seen for these prostate cancer biomarkers," Torben Ømtoft, a professor at Aarhus University Hospital, said in a statement.

Exiqon CEO Lars Kongsbak said the deal helps accelerate the Copenhagen-based firm's prostate cancer diagnostic program because it would have taken years for the firm to assess the prognostic value of biomarkers on its own. 

Financial details of the agreement were not disclosed.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.